---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-094359"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:22:07.704289+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%

## Summary
- Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.
- Cash and equivalents $19.4M as of June 30, 2024; projected runway into Q2 2026.
- Pivotal Phase 3 STRIVE-ON safety trial surpassed 50% enrollment; completion expected late 2024 to early 2025.
- NDA submission to FDA for GTX-104 anticipated in first half of calendar 2025.
- R&D expenses rose to $2.7M from $1.1M, driven by GTX-104 clinical activities.

## SEC filing metadata
- accession: 0000950170-24-094359
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/0000950170-24-094359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/acst-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-094359
- JSON: https://secwatch.observer/filing/0000950170-24-094359.json
- Plain text: https://secwatch.observer/filing/0000950170-24-094359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.